SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VISX

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Charlie Smith who wrote (409)3/6/1998 10:27:00 PM
From: Amy Feller  Read Replies (1) of 1754
 
Charlie..

Here's more from the report (I would type it all, but it was a poor
fax and difficult to read)

"LVC procedure royalties will drive earnings in 1998 and beyond. VISX
generates its revenue largely through the worldwide sales of its LVC
systems and highly profitable royalty fees from each LVC procedure
that is performed in the US. While equipment sales were historically
responsible for the majority of revenue and earnings, this
top-line component should trend downward through the year 2000,
reflecting the emergence of new competitors in a domestic market that
has probably already surpassed the 50% saturation point. The LVC
procedure royalties that are paid through a partnership called
Piller Point should account for about 65% of 1998 revenue and will
continue to be the largest and most profitable portion of the
company's revenue stream over the next several years. There were
approximately 195,000 LVC procedures performed in 1997 and we expect
the industry to perform 350,000 procedures this year. We continue to
believe that one million individuals in the US will undergo laser
vision correction in the year 2000.

--Strong bottom line comparisons in coming quarters and a healthy
cash horde. Accompanying the continued robust growth in LVC procedures
will be accelerating bottom-line gains. While we look for 1998
earnings to rise more than 50% in the first half of the year, we are
estimating FULLY TAXED (ed note: my CAPS) March quarter earnings
of $.27 per share (compared with $.12 a year ago) and earnings of
$.30 for the three month period ending June 30 (versus $0.14 in the
prior year). Operating margins will improve dramatically, reflecting
gross margin expansion and leverage within other expense categories.
Moreover, VISX had $101 Million in cash (more than $6.50 share) and
no long term debt as of Dec 31. The company has been steadily
generating cash for the past two years.

###
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext